federal-policy

Hawaiʻi joins 10 states in the Certified Community Behavioral Health Clinic Medicaid Demonstration, bringing enhanced funding for mental health and substance use disorder treatment.

DEA identifies 5-chloro desmethyl chlorphine—a new class of ultra-potent synthetic opioids—in Tennessee seizure. Learn the risks and how to stay safe.

DEA issues urgent safety advisory as fentanyl is increasingly combined with xylazine, nitazenes, cychlorphine, and medetomidine—substances that can defeat standard overdose reversal.

Alaska, Colorado, Hawaii, Louisiana, Maryland, Mississippi, Montana, North Dakota, Washington, and West Virginia join the CCBHC Medicaid Demonstration Program, bringing comprehensive mental health and addiction services to millions.

SAMHSA's April 2026 guidance prohibits federal grant funds from purchasing fentanyl test strips. Learn what this means for harm reduction programs and how to stay safe.

CDC and DEA warn that medetomidine — a potent veterinary sedative — is spreading in the illegal fentanyl supply, causing severe withdrawal and complicating overdose response.

Bipartisan bill would establish dedicated funding stream for multi-jurisdictional drug task forces combating opioid trafficking across Washington state.

Federal health officials warn about cychlorphine, a potent synthetic opioid linked to 55+ deaths nationwide. Learn the risks, recognition signs, and life-saving response strategies.

The FDA has extended the shelf life of over-the-counter naloxone nasal spray from 3 to 4 years. Here's what families and individuals should know about storage, access, and emergency preparedness.